Acadia Pharmaceuticals Stock Z Score
| ACAD Stock | USD 17.14 0.27 1.55% |
ACADIA | Z Score |
ACADIA Pharmaceuticals Company Z Score Analysis
ACADIA Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
ACADIA Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for ACADIA Pharmaceuticals is extremely important. It helps to project a fair market value of ACADIA Stock properly, considering its historical fundamentals such as Z Score. Since ACADIA Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ACADIA Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ACADIA Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, ACADIA Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
ACADIA Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACADIA Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ACADIA Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ACADIA Pharmaceuticals by comparing valuation metrics of similar companies.ACADIA Pharmaceuticals is currently under evaluation in z score category among related companies.
ACADIA Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ACADIA Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ACADIA Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ACADIA Pharmaceuticals' value.| Shares | Palo Alto Investors, Llc | 2023-12-31 | 2.4 M | First Trust Advisors L.p. | 2023-12-31 | 1.8 M | Millennium Management Llc | 2023-12-31 | 1.8 M | Emerald Advisers, Llc | 2023-12-31 | 1.6 M | Goldman Sachs Group Inc | 2023-12-31 | 1.6 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.5 M | Norges Bank | 2023-12-31 | 1.4 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | Baker Bros Advisors Lp | 2023-12-31 | 42.9 M | Vanguard Group Inc | 2023-12-31 | 13.4 M |
ACADIA Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0686 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 2.4 B | ||||
| Shares Outstanding | 164.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 99.56 % | ||||
| Number Of Shares Shorted | 11.2 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 6.54 X | ||||
| Price To Sales | 3.89 X | ||||
| Revenue | 726.44 M | ||||
| Gross Profit | 145.49 M | ||||
| EBITDA | (67.83 M) | ||||
| Net Income | (61.29 M) | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 57.2 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 2.62 X | ||||
| Cash Flow From Operations | 16.7 M | ||||
| Short Ratio | 4.66 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 29.62 | ||||
| Number Of Employees | 597 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 2.78 B | ||||
| Total Asset | 748.96 M | ||||
| Retained Earnings | (2.43 B) | ||||
| Working Capital | 361.87 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
| Net Asset | 748.96 M |
About ACADIA Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACADIA Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACADIA Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACADIA Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ACADIA Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ACADIA Stock
| 0.8 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against ACADIA Stock
| 0.89 | RZLT | Rezolute Trending | PairCorr |
| 0.86 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
| 0.82 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.79 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb Financial Report 25th of April 2024 | PairCorr |
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ACADIA Pharmaceuticals Piotroski F Score and ACADIA Pharmaceuticals Valuation analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.